Aradigm Announces Successful Completion of Phase 2b Trials of


                         The AERx(R) 
                            Pain Management System 


  HAYWARD, Calif., Dec. 19 /PRNewswire/ -- 
Aradigm Corporation (Nasdaq: ARDM) today announced that it has successfully 
completed Phase 2b clinical trials for its morphine AERx (R) Pain Management 
System (AERx PMS).  The system delivers morphine via the AERx pulmonary drug 
delivery technology for the management of acute and breakthrough pain.  Over 
100 patients were treated in two separate studies recently completed.  
"The completion of this phase of development of our AERx PMS represents a 
significant milestone for our company.  We are particularly pleased that the 
efficacy of our product is comparable to intravenous morphine.  We were also 
pleased that AERx PMS provides significantly faster pain relief than immediate 
release oral morphine commonly used for the management of breakthrough pain," 
said Rick Thompson, president and CEO of Aradigm.  "With these safety and 
efficacy data, we have achieved our goals for this stage of development."  
In a study of 16 patients with breakthrough pain from advanced cancer, 
AERx morphine demonstrated significantly faster onset of pain control and 
comparable overall pain relief when compared to immediate release oral 
morphine solution.  More patients selected AERx morphine as the treatment of 
choice for further management of their breakthrough pain compared to the oral 
morphine solution.  
In a separate study of 89 patients with acute postoperative pain, the AERx 
PMS was shown to provide pain relief comparable to intravenous morphine when 
given in similar doses. The study also demonstrated that similar doses of AERx 
morphine and intravenous morphine were superior to placebo on pain control, 
using standard pain intensity and pain relief endpoints. Adverse events for 
the AERx morphine were comparable to those seen in patients dosed with IV 
morphine.  The postoperative population is a widely accepted model for 
studying the effectiveness of medications for acute pain.  
"The morphine delivery system being developed by Aradigm represents a 
significant breakthrough in pain management.  With its rapid onset of pain 
relief, it provides unique in-home management of pain in cancer patients," 
says Richard Rauck M.D., an anesthesiologist and pain control expert at Wake 
Forest University, Winston Salem, NC, who also was an investigator on the AERx 
morphine cancer pain study.  
The detailed study results will be presented at scientific conferences 
during 2002.  
Following completion of this stage of development, Aradigm will be working 
with its partner GlaxoSmithKline, to determine the next steps for the AERx 
morphine program.  Future development plans for the product, including the 
timing of Phase 3 clinical trials will be announced at a later date.  
Aradigm is working to improve the quality of life of patients by 
developing aerosol-based drug delivery alternatives to injectable 
therapeutics.  The Company's advanced pulmonary delivery technologies provide 
leading pharmaceutical and biotechnology partners with effective drug delivery 
solutions.  Aradigm's technology uses liquid drug formulations that are 
similar to the injectable forms and minimize the potential for safety concerns 
when delivered by the pulmonary route.  Current development programs focus on 
diabetes, pain management, and the pulmonary delivery of existing and emerging 
biotech therapeutics.  
Based in Hayward, California, Aradigm is currently developing products for 
diabetes management with Novo Nordisk A/S, the world leader in insulin and 
diabetes care, and breakthrough and acute pain management for GlaxoSmithKline, 
a world leader in oncology therapy and supportive care. In addition, Aradigm 
has three additional partner-funded programs and a gene therapy effort funded 
through the National Institutes of Health. More information about Aradigm can 
be found at www.aradigm.com. Investors may also request company information 
via email by directing inquiries to investor@aradigm.com.  
  Please note:  
Except for the historical information contained herein, this news release 
contains forward-looking statements that involve risk and uncertainties, 
including the timely availability and acceptance of new products, the impact 
of competitive products and pricing, and the management of growth, as well as 
the other risks detailed from time to time in Aradigm Corporation's Securities 
and Exchange Commission (SEC) filings, including the company's Annual Report 
on Form 10-K as amended and its Quarterly Reports on Form 10-Q.  


       AT ARADIGM CORPORATION: 
     Tracy Hudson 
     Investor Relations Coordinator 
     (510) 265-9000 
       INVESTORS: 
     Kari Lampka 
     Feinstein Kean Healthcare 
     (617) 577-8110 
       MEDIA: 
     Claire Campbell 
     Ogilvy Public Relations Worldwide 
     (310) 407-7900 
                      MAKE YOUR OPINION COUNT -  Click Here 


           http://tbutton.prnewswire.com/prn/11690X56021685 
  

SOURCE  Aradigm Corporation  
-0-                             12/19/2001  
/CONTACT: Tracy Hudson, Investor Relations Coordinator of Aradigm, 
+1-510-265-9000; or INVESTORS: Kari Lampka of Feinstein Kean Healthcare, 
+1-617-577-8110; or MEDIA: Claire Campbell of Ogilvy Public Relations 
Worldwide, +1-310-407-7908/  
/Web site:  http://www.aradigm.com/  
CO:  Aradigm Corporation 
ST:  California 
IN:  BIO MTC 
SU:  
-0- Dec/19/2001 11:15 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.